The clinical trial involving aliskiren, a renin inhibitor, was stopped prematurely due to adverse events (hyperkalemia, hypotension, and cardiac arrest) and due to lack of benefit when compared to placebo [86]. The gene discussed is REN; the disease is Hyperkalemia.